Interpreting Cytology Specimens

Interpreting Cytology Specimens

Structures cytology interpretation with Bethesda system for cervical and other body site classifications.

Why This Skill Exists

Cytology interpretation directly governs cancer screening, triage, and management pathways for millions of patients annually. The Bethesda System for Reporting Cervical Cytology (TBS), now in its third edition, is the universal standard for Pap test reporting and links each diagnostic category to specific ASCCP management guidelines. Errors in cytology — false negatives in cervical screening, missed malignant cells in effusions, or inadequate specimen assessments — have well-documented consequences including delayed cancer diagnosis and medicolegal exposure.

CLIA regulations (42 CFR 493.1257) impose specific workload limits for cytotechnologists (no more than 100 slides per 24 hours), require 10% random rescreening, mandate cyto-histo correlation, and demand annual statistical review. CAP accreditation adds checklist requirements for gynecologic and non-gynecologic cytology (CYP checklist series). This skill ensures that every cytology interpretation follows TBS and CAP standards with defensible documentation.

Checkpoint A: Pre-Draft Intake (Mandatory)

1. Specimen type — Cervical (Pap), body fluid, FNA, urine, bronchial wash, or other? Default: cervical Pap.
2. Preparation method — Liquid-based (ThinPrep, SurePath) or conventional smear? Default: liquid-based.
3. Clinical history — LMP, hormonal status, prior cytology/biopsy, HPV status, clinical impression? Default: not provided; flag [VERIFY].
4. HPV co-test result — If cervical, is there a concurrent HPV result (positive, negative, genotype-specific)? Default: pending.
5. Prior cytology history — Previous abnormal Pap results and follow-up? Default: none on file.
6. Adequacy concerns — Were any pre-analytical issues noted (scant cellularity, obscuring blood, drying artifact)? Default: none noted.
7. Ancillary testing — Are cell block, immunostains, or molecular testing needed? Default: per reflex protocol.

Documents to Request

• Cytology requisition with clinical history and LMP
• Prior cytology reports (3-year look-back per ASCCP)
• Prior biopsy/histology reports for cyto-histo correlation
• HPV test result (co-test or reflex)
• Colposcopy reports if applicable
• FNA radiology report (ultrasound, CT guidance) for aspirates
• Cell block H&E slides and ancillary stain results

Step 1: Specimen Adequacy Assessment

Evaluate specimen adequacy as the mandatory first element of every cytology report per TBS:

Cervical cytology adequacy criteria:

Non-gynecologic cytology adequacy:

• Body fluids: Assess cellularity relative to clinical context; a paucicellular transudative effusion may be adequate
• FNA: At least 6 groups of 10+ benign follicular cells for thyroid (Bethesda System for Reporting Thyroid Cytopathology)
• Urine: No absolute cell count; assess by clinical context, but note if acellular or degenerated

Document any quality indicators: air-drying artifact, lubricant contamination, scant transformation zone component (TZC/EC), or obscuring elements.

Step 2: Systematic Screening and Interpretation

Cervical Cytology — The Bethesda System (TBS 3rd Edition)

Apply TBS categories in hierarchical order:

1. NILM (Negative for Intraepithelial Lesion or Malignancy): Normal or reactive/reparative changes, organisms (Trichomonas, Candida, bacterial vaginosis shift, Actinomyces, HSV).
2. Epithelial Cell Abnormalities — Squamous:
   • ASC-US: Atypical squamous cells of undetermined significance
   • ASC-H: Atypical squamous cells, cannot exclude HSIL
   • LSIL: Low-grade squamous intraepithelial lesion (HPV, CIN 1)
   • HSIL: High-grade squamous intraepithelial lesion (CIN 2, CIN 3)
   • SCC: Squamous cell carcinoma
3. Epithelial Cell Abnormalities — Glandular:
   • AGC: Atypical glandular cells (qualify: endocervical, endometrial, or NOS)
   • AGC favor neoplastic: Atypical glandular cells, favor neoplastic
   • AIS: Endocervical adenocarcinoma in situ
   • Adenocarcinoma: Endocervical, endometrial, extrauterine, or NOS

Non-Gynecologic Cytology

• Body fluids: Negative for malignancy, atypical cells (favor reactive vs. favor neoplastic), suspicious for malignancy, positive for malignancy. Classify cell type.
• Thyroid FNA: Apply Bethesda System for Reporting Thyroid Cytopathology (BSRTC) categories I-VI.
• Pancreaticobiliary FNA: Apply Papanicolaou Society guidelines.
• Urine: Apply Paris System for Reporting Urinary Cytology (TPSRUC) categories.

Step 3: Ancillary Studies and Correlation

• HPV reflex testing: For ASC-US, reflexing to hrHPV is standard per ASCCP 2019 guidelines. Document result and management implication.
• Immunocytochemistry: p16/Ki-67 dual stain for triage of HPV-positive/ASC-US or LSIL. Calretinin, BerEP4, MOC-31, D2-40 for mesothelial vs. adenocarcinoma in effusions.
• Cell block evaluation: If cell block was prepared, correlate with liquid-based or smear findings. Apply IHC panel for tumor typing on cell block material.
• Molecular testing: HPV genotyping (16, 18 vs. other hrHPV), UroVysion FISH for urine cytology, flow cytometry on body fluids with suspected lymphoma.

Step 4: Cyto-Histo Correlation

Per CLIA 42 CFR 493.1274 and CAP CYP.05900:

• Correlate all positive or atypical cervical cytology with subsequent biopsy within 6 months.
• Document correlation as: concordant, minor discordance (one grade), or major discordance (two or more grades).
• Major discordances require review by cytopathologist and may trigger slide re-review.
• Maintain a cyto-histo correlation log with quarterly statistical review.
• For non-gyn cytology, correlate FNA diagnoses with surgical pathology when excision follows.

Step 5: Report Assembly and Sign-Out

Construct the final report per TBS format:

1. Specimen type and preparation: State method (ThinPrep, SurePath, conventional, FNA).
2. Adequacy statement: Must appear as the first diagnostic line.
3. General categorization: NILM or Epithelial Cell Abnormality.
4. Interpretation/Result: Specific TBS category with qualifiers.
5. Ancillary testing: HPV result, immunostains, molecular tests.
6. Educational notes/suggestions: Include ASCCP management recommendation when applicable (e.g., "Per ASCCP 2019 guidelines, HPV 16/18 positive ASC-US warrants direct referral to colposcopy").
7. Comment: Address any discordance, limitations, or recommendations.

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the adequacy statement the first element of the interpretation and does it meet TBS criteria?
2. Does the TBS category exactly match the standardized terminology (no hybrid or non-standard terms)?
3. Is the HPV co-test or reflex result documented and correlated with the cytologic interpretation?
4. For non-gyn specimens, is the appropriate reporting system used (Paris, BSRTC, Papanicolaou Society)?
5. Are cyto-histo correlation requirements met for any prior abnormal results?

Quality Audit

• Specimen adequacy evaluated and documented as first diagnostic element
• TBS terminology used verbatim for cervical cytology categories
• HPV co-test or reflex result integrated into interpretation
• ASCCP management recommendation included where applicable
• Non-gynecologic specimens classified per appropriate system (Paris, BSRTC)
• Cell block findings correlated with cytology preparation
• FNA adequacy assessed per site-specific criteria (e.g., 6 groups for thyroid)
• Cyto-histo correlation documented for cases with prior tissue diagnosis
• Workload recorded per CLIA 42 CFR 493.1257 (max 100 slides/24 hours)
• 10% rescreening of negative cases documented
• Quarterly statistical review completed with sensitivity/specificity metrics
• Report turnaround within institutional and CAP benchmarks

Guidelines

• Always report specimen adequacy as the first element; never omit it even for positive cases
• Use exact TBS 3rd edition terminology for cervical cytology; do not modify or abbreviate diagnostic categories
• For thyroid FNA, apply Bethesda System for Reporting Thyroid Cytopathology with implied risk of malignancy for each category
• Include ASCCP management recommendations as educational notes when the diagnosis triggers a specific guideline action
• Maintain strict CLIA workload limits and document daily case counts
• Correlate all abnormal cervical cytology with tissue follow-up within 6 months; escalate unresolved discordances
• For body fluid cytology, always state whether findings are negative, suspicious, or positive for malignancy, and classify the malignant cell type when positive
• Never downgrade a cytologic interpretation based solely on clinical expectation; document morphologic basis for every diagnosis